title: Personal experience on treatment of colorectal liver metastases: a multidisciplinary approach.
abstract: Diagnosed colorectal cancer patients presents liver metastases at presentation in 25% of cases, an another 25% of patients will develop hepatic recurrence during follow-up period. Natural history of disease in untreated patients is sad without long term survivors. The only chance of curative treatment is surgical resection. Aim of this study was to evaluate recurrence and survival in the multimodal approach of colorectal liver metastases patients.
  
  
  METHODS
  From 1990 to 2003, 212 colorectal cancer liver metastases patients were observed at the "Regina Elena" cancer institute of Rome, the 48.8% of cases were synchronous. Of 185 patients with minimum follow-up of 12 months, 80 were surgically resected, while 105 were not. Major resection was possible in 45.3% of cases and 66.1% of them were radicals. Tweny were treated by surgery alone, 65% were resected after i.v. chemotherapy, in the last 10% resection followed HAI chemotherapy. Of non resected patients, in the 36.2% i.v. chemotherapy was administered, 26.1% were submitted to HAI chemotherapy, in 18.9% others treatments were carried out and 18.8 were untreated.
  
  
  RESULTS
  Operative mortality was contained to 2.5%. The hepatic recurrence was observed in 50.5% of cases while extrahepatic was in the 13.6%. In the resected cases the 5-yr. Overall survival was 38.8%, the disease-free survival decreased to 14.7% with a median time to progression of 15 months. The liver recurrence-free survival was 31.3%. Really bad prognopsis was observed in the non resected patients with none survived at 5 years and 3-yr overall survival of 18.7%.
  
  
  CONCLUSIONS
  In selected patients the multimodality approach to treatment of hepatic metastases showed satisfactory results in terms of local and distal control of disease. Long term survivors were observed in the our experience.
authors.affiliation: Colorectal Cancer Project, Department of Surgery, Regina Elena Cancer Institute, Rome, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Mancini
authors.forename: G
authors.initials: G
authors.lastname: Ettorre
authors.forename: G
authors.initials: G
authors.lastname: Vennarecci
authors.forename: I
authors.initials: I
authors.lastname: Sperduti
authors.forename: C
authors.initials: C
authors.lastname: Garufi
authors.forename: A
authors.initials: A
authors.lastname: Esposito
authors.forename: M
authors.initials: M
authors.lastname: Cosimelli
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D003131:Combined Modality Therapy; D013505:Digestive System Surgical Procedures; D018572:Disease-Free Survival; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents